Propanc reports preclinical pancreatic cancer data for PRP drug candidate
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit
August 27, 2026 8:30 AM EDTDifferentiated Profile versus RAS-Targeted Approaches Including Revolution Medicines Daraxonrasib
MELBOURNE, Australia, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (Propanc or the Company), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced compelling new preclinical and early translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC).
In orthotopic and patient-derived xenograft (PDX) models of advanced PDAC, three-times-weekly intravenous PRP achieved:
Greater than 90%, mean, tumor growth inhibition versus vehicle controls (p <... class="raquo" href="Globe+Newswire/Propanc+Biopharma+Announces+Compelling+New+Preclinical+Pancreatic+Cancer+Data+for+PRP+Showing+%3E90%25+Tumor+Growth+Inhibition+and+%3E2.5-Fold+Survival+Benefit/26985400.html">More